2nd Apr 2025 09:51
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company."
Current stock price: 1,180.00, up 1.3% on Wednesday morning in London.
12-month change: up 25%
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
4basebio Plc